Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis
Status:
Active, not recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether oral etrasimod is a safe and effective
treatment for moderately to severely active ulcerative colitis.